January 2022Milestones

Dr. Susan Kahn renewed as Tier 1 Canada Research Chair in Venous Thromboembolism

Dr. Susan Kahn, a Senior Investigator in the Lady Davis Institute (LDI) at the JGH, has been renewed as a Tier 1 Canada Research Chair in Venous Thromboembolism for another seven years,  in recognition of the importance of her research.

“The renewal of this research chair will be tremendously helpful in supporting my team’s ongoing research efforts and in enhancing the quality of life of those impacted by VTE, both in Canada and globally,” says Dr. Kahn.

As a world expert in venous thromboembolism (VTE), Dr. Kahn is the founder and Director of the Centre of Excellence in Thrombosis and Anticoagulation Care, based at the JGH. It is one of only three Royal College-approved training sites in thrombosis in Canada.

VTE, the formation of blood clots in the veins, is an under-diagnosed and serious, yet preventable, cardiovascular disease that affects people of all ages and ethnicities. It is the third-most common cardiovascular condition after heart attack and stroke.

Dr. Kahn, a Professor of Medicine at McGill University, has devoted her career to reducing the incidence of VTE, enhancing its diagnosis and therapeutic management, and improving patient safety and outcomes in Canada and globally.

Under her leadership, the JGH has been a trailblazer in developing VTE prevention protocols and anticoagulation guidelines at the national and international level.

The hospital’s unique, multidisciplinary Thrombosis Program includes patient care, training, education and internationally recognized research components.

“On behalf of the entire LDI, we congratulate Dr. Susan Kahn and all holders of Canada Research Chairs for their commitment and success at achieving excellence,” said Stephen Robbins, Director of the LDI.

Previous article

Dr. Lawrence Rosenberg named among most inspiring CEOs of 2021

Next article

Researchers identify protective gene variant against COVID-19